title: Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.
abstract: Although still in very early stages of clinical development, the combination of antiangiogenics with contemporary chemoradiotherapy regimens has emerged as a feasible and promising approach to many cancers. We review the rationale and the current understanding of antiangiogenics and their therapeutic potential in combination with chemoradiotherapy. Finally, we offer a perspective on future research directions aimed at making this complex therapeutic approach successful in the clinic.
authors.affiliation: Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA. duda@steele.mgh.harvard.edu
authors.forename: Dan G
authors.initials: DG
authors.lastname: Duda
authors.forename: Rakesh K
authors.initials: RK
authors.lastname: Jain
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Willett
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D003131:Combined Modality Therapy; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000532:radiotherapy*; D018714:Radiotherapy, Adjuvant